Abbott Laboratories at JPMorgan Healthcare Conference Transcript

Jan 14, 2020 / 05:00PM GMT
Robert Justin Marcus - JP Morgan Chase & Co, Research Division - Analyst

Good morning, everyone. We'll get started here. I'm Robbie Marcus, the medtech analyst at JPMorgan. I'm very happy to have Robert Ford, the incoming CEO of Abbott joining us today.

Robert B. Ford - Abbott Laboratories - President, COO & Director

Well, thank you for having us, Robbie. It's great to be here. We've got an exciting time at Abbott right now. I'd like to thank the audience for your interest at Abbott.

Questions and Answers:

Robert Justin Marcus - JP Morgan Chase & Co, Research Division - Analyst

Maybe we could kick it off. Abbott has established an impressive track record of delivering organic sales growth in the 7% to 8% range, no small feat for a company with $30 billion in sales. Now the company has often reiterated that you expect this type of performance to continue over time. Maybe share with us why you feel confident Abbott can sustain that level of growth going forward.

Robert B. Ford
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot